The central challenge tackled by this research lies in the immunosuppressive nature of myeloid cells—immune cells abundant within glioblastoma tumors—that often dampen the body’s natural anti-cancer responses. These myeloid cells form a protective milieu that enables residual cancer cells to evade destruction after surgical excision, contributing to tumor recurrence. The research team asked whether reprogramming these immune cells immediately after tumor resection could convert this suppressive environment into a pro-inflammatory, cancer-fighting one.

To achieve this, the investigators engineered a wafer-like implant made of crosslinked cyclodextrin, a sugar-based, biodegradable polymer capable of sustained drug release. This implant, aptly nicknamed CANDI, is designed to be placed in the brain cavity created after tumor removal surgery. Its slow-release mechanism delivers a potent cocktail of small molecule immune modulators directly to the myeloid cells infiltrating the surgical site. By precisely targeting myeloid cells in situ, the wafer aims to enhance local immune activation without systemic toxicity.

Initial in vitro experiments confirmed that the cyclodextrin wafer not only successfully released the immune-modulating agents but was also effectively engulfed by tumor-associated macrophages—key myeloid cells in glioblastoma. Upon internalization, these immune cells were reprogrammed to produce interleukin-12 (IL-12), a cytokine critical for stimulating robust anti-tumor immunity. IL-12 promotes the recruitment and activation of cytotoxic T cells, boosting the immune system’s ability to eradicate remaining glioblastoma cells.

In vivo studies in mouse models of glioblastoma provided compelling evidence for the wafer’s efficacy. When implanted following surgical tumor removal, CANDI resulted in long-term tumor-free survival in over half of the mice treated, a remarkable improvement compared to controls. Immune profiling confirmed increased infiltration and activation of T cells at the tumor site, validating the immune-modulating strategy’s ability to transform the tumor microenvironment from immunosuppressive to immunostimulatory.

Crucially, the team extended their investigations to freshly harvested human glioblastoma tissues maintained ex vivo, demonstrating that the wafer induced similar immunological changes in human tumors. This translational aspect strengthens the potential clinical relevance of the implant-mediated therapy and signals feasibility for eventual human trials.

This breakthrough holds substantial implications for the future of glioblastoma treatment. While immunotherapies have revolutionized management of various cancers, no FDA-approved immunotherapy yet exists for glioblastoma due to its highly immunosuppressive microenvironment and poor drug delivery across the blood-brain barrier. By directly implanting an immunomodulatory device into the surgical cavity, this approach circumvents systemic delivery challenges and may complement existing standards of care, such as chemo- and radiotherapy, potentially extending patient survival and improving quality of life.

Looking ahead, the researchers are focused on refining the wafer’s design to optimize drug release kinetics for human applications and scaling up production consistent with clinical manufacturing standards. They are preparing to enter phase I clinical trials, with the goal of integrating this implantable immunotherapy into surgical oncology protocols in the near future.

The publication credits Christopher S. Garris, Hyung Shik Kim, Juhyun Oh, Elias A. Halabi, Moonhyun Choi, Sepideh Parvanian, and Rainer Kohler as co-authors, emphasizing the collaborative interdisciplinary efforts that made this innovation possible. Financial support was provided by grants from the National Institutes of Health, as well as the Swiss Institute for Experimental Cancer Research and the German Academic Exchange Service.

This pioneering strategy exemplifies how converging advances in biomaterials, immunology, and neurosurgery can yield transformative therapies for some of medicine’s most intractable diseases. If successful in human trials, the CANDI implant could mark a paradigm shift in glioblastoma management, leveraging the body’s own immune arsenal to prevent cancer relapse in a disease that has long defied durable control.

Such implant-mediated immunotherapies may soon extend beyond glioblastoma to other solid tumors characterized by immunosuppressive microenvironments, broadening the therapeutic impact of this novel modality. As this research progresses, it reinforces the critical role of local immune modulation in enhancing cancer control and the promise of biomaterials to precisely deliver such interventions.

This study stands at the forefront of personalized medicine, transforming the surgical bed from a vulnerable site of residual disease into a battleground of immune-mediated tumor eradication. The innovation paves the way for integrating immunotherapy directly into surgical practice, potentially revolutionizing outcomes for patients afflicted by devastating cancers like glioblastoma.

Subject of Research: Animals
Article Title: Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence
News Publication Date: 22-Oct-2025
Web References: DOI: 10.1038/s41551-025-01533-2
References: Kaiser, Y., et al. Nature Biomedical Engineering, 2025
Image Credits: Not provided

Adoptive immunotherapy, especially CAR T cell therapy, has emerged as a powerful weapon against hematologic malignancies and other diseases by engineering a patient’s T cells to express CARs that recognize tumor antigens. Traditionally, this involves harvesting T cells from patients, genetically modifying them outside the body, expanding these cells, and reinfusing them—a process that requires extensive infrastructure, time, and significant costs. The reliance on ex vivo manipulation also exposes cells to potential contamination, and manufacturing variability can impact therapeutic efficacy. Addressing these limitations has been a persistent scientific challenge, one that has inspired new strategies centered on simplifying and streamlining T cell engineering.

Theresa Hunter and her team have pioneered a transformative method whereby lipid nanoparticles, engineered with a novel ionizable lipid designated L829, are conjugated with antibodies targeting CD5—a protein prominently expressed on T cells. These CD5-targeted LNPs are designed to evade the liver’s reticuloendothelial system, a common sink for systemically administered nanoparticles, thereby enhancing the specificity and efficacy of T cell delivery. By encapsulating mRNA encoding CAR constructs, the tLNPs facilitate the direct translation of these sequences within T cells in vivo, bypassing the integration risks associated with DNA-based vectors.

The advantages of utilizing mRNA are profound. Unlike DNA, mRNA remains transient in the cytoplasm and avoids genomic integration, mitigating concerns regarding insertional mutagenesis and other long-term genetic alterations. This transient expression can also be advantageous where temporary modulation of immune response is desired. Yet, the chief hurdle has been achieving selective and efficient in vivo delivery to T cells, which conventional LNPs have struggled with due to predominant hepatic accumulation and off-target effects.

By leveraging the specificity afforded by CD5-targeting and the biophysical properties of the ionizable lipid L829, the researchers achieved markedly improved biodistribution of their nanoparticles. In preclinical tests spanning murine, rat, and nonhuman primate models, these CD5-L829-tLNPs demonstrated reduced liver uptake and enhanced localization within T cell populations. Such precision in targeting heralds a new frontier in immunotherapy, allowing for more controlled, predictable therapeutic outcomes while limiting systemic toxicity.

Beyond biodistribution, the functional efficacy of these in vivo engineered CAR T cells was rigorously evaluated. Blood samples derived from patients with autoimmune disorders revealed that the tLNP approach could equip diseased T cells with CAR constructs at efficiencies paralleling those achieved with healthy donor cells. Impressively, these remodeled T cells selectively eliminated corresponding B cells responsible for pathogenic autoantibody production, suggesting potent therapeutic potential against autoimmunity.

To further corroborate the therapeutic promise, humanized mouse models, engrafted with primary human immune cells, were administered a single intravenous dose of the targeted nanoparticles. Within hours, recipient mice showcased robust B cell depletion that persisted for up to fourteen days, indicating not only rapid induction but also durable immune modulation via this novel approach. This in vivo paradigm minimizes the procedural complexities traditionally associated with adoptive cell transfer therapies.

Moreover, when applied in a leukemia xenograft model, repeated dosing of the tLNPs led to near-complete clearance of tumor burden. This outcome underscores the platform’s versatility and strength in mounting potent antitumor responses. The direct and scalable nature of in vivo CAR T cell generation may democratize access to these therapies, making effective immunotherapy feasible outside specialized centers and possibly reducing treatment costs.

The implications of this research extend beyond oncology, offering a blueprint for treating a spectrum of immune-mediated diseases. By enabling rapid, on-demand reprogramming of immune cells through safe, non-integrative mRNA delivery systems, this technology could hasten clinical responses and provide personalized treatment options for patients with refractory autoimmune conditions and beyond.

Despite these remarkable advancements, important considerations linger regarding the fine-tuning and clinical translation of this technology. The transient nature of mRNA expression could necessitate repeated dosing protocols, raising questions about immune memory formation and long-term efficacy. Furthermore, off-target immune activation and nanoparticle immunogenicity must be carefully monitored and mitigated through further optimization.

This approach exemplifies a paradigm shift in cellular immunotherapy, transitioning from cumbersome ex vivo manipulations to a seamless, minimally invasive in vivo reprogramming. As the field embraces this innovation, broader applications across infectious diseases, transplant medicine, and tolerance induction in autoimmune pathologies appear increasingly attainable.

In sum, the pioneering work of Hunter and colleagues heralds a transformative era where immunological engineering is not confined to manufacturing suites but can instead be delivered systemically with precision, safety, and efficacy. Targeted lipid nanoparticle-mediated delivery of functional mRNA directly to T cells paves the way for next-generation therapies that are more accessible, adaptable, and potent—a prospect poised to reshape the future of medicine.

Subject of Research: In vivo generation of CAR T cells using targeted lipid nanoparticles for cancer and autoimmune disease treatment

Article Title: In vivo CAR T cell generation to treat cancer and autoimmune disease

News Publication Date: 19-Jun-2025

Web References: http://dx.doi.org/10.1126/science.ads8473

Keywords: CAR T cells, in vivo engineering, lipid nanoparticles, mRNA delivery, immunotherapy, cancer treatment, autoimmune disease, targeted delivery, ionizable lipids, adoptive cell therapy, CD5 targeting, gene therapy